ZOLADEX

Trials studying ZOLADEX

• phase1A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancerrecruitingn=88
• phase2A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancerrecruitingn=600
• phase3Phase IIIb Study of Ribociclib + ET in Early Breast Cancerrecruitingn=1,400
• phase1[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Canceractive not recruitingn=28
• phase2Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)completedn=57
• phase4Roll-over Study to Allow Continued Access to Ribociclibactive not recruitingn=134
• phase3Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracersrecruitingn=493
• phase1Neo-DAB: Darolutamide and Abemaciclib in Prostate Canceractive not recruitingn=9